Arturo Molina - Nov 15, 2023 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Medical Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD
Stock symbol
PTGX
Transactions as of
Nov 15, 2023
Transactions value $
-$30,012
Form type
4
Date filed
1/4/2024, 08:09 PM
Previous filing
Jan 18, 2023
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Sale -$30K -1.85K -7.58% $16.24 22.5K Nov 15, 2023 Direct F1
transaction PTGX Common Stock Award $0 +26.3K +116.53% $0.00 48.8K Jan 2, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Award $0 +97.5K $0.00 97.5K Jan 2, 2024 Common Stock 97.5K $23.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.
F2 Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F3 The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.